<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01781572</url>
  </required_header>
  <id_info>
    <org_study_id>CMEK162X2114</org_study_id>
    <secondary_id>C4211005</secondary_id>
    <nct_id>NCT01781572</nct_id>
  </id_info>
  <brief_title>A Phase Ib/II Study of LEE011 in Combination With MEK162 in Patients With NRAS Mutant Melanoma</brief_title>
  <official_title>A Phase Ib/II, Multicenter, Open Label, Study of LEE011 in Combination With MEK162 in Adult Patients With NRAS Mutant Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In the phase Ib, the primary purpose is to establish the maximum tolerated dose&#xD;
      (MTD)(s)/recommended phase ll dose (RP2D) and schedule of LEE011 and MEK162 orally&#xD;
      administered combination. Once the MTD(s)/RP2D have been determined for each tested schedule,&#xD;
      additional patients will be enrolled in the phase II portion of the study at the RP2D on the&#xD;
      chosen schedule in order to assess the anti-tumor activity of the combination in addition to&#xD;
      continued evaluation of safety.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Actual">February 20, 2018</completion_date>
  <primary_completion_date type="Actual">January 15, 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Dose Limiting Toxicities (Phase Ib)</measure>
    <time_frame>first 28 days of treatment</time_frame>
    <description>To estimate the maximum tolerate doses (MTDs) and/or identify the RP2D and schedule of LEE011 and MEK162 combination. A dose-limiting toxicity (DLT) was defined as an AE or clinically significant abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurred within the first cycle of treatment with ribociclib and binimetinib.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate (ORR) (Phase II)</measure>
    <time_frame>Approximately 12 months after the FPFV</time_frame>
    <description>ORR is the proportion of patients with best overall response of complete response (CR) or partial response (PR) by month 2 assessed according to RECIST 1.1 criteria. ORR is done to describe the anti-tumor activity of LEE011 and MEK162 combination. The primary analysis of the ORR was based on the Investigator's assessment of overall lesion responses per RECIST 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration-time Profile (AUCtau) of LEE011 (Phase Ib)</measure>
    <time_frame>Cycle 1 Day 1</time_frame>
    <description>To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration-time Profile (AUCtau) of MEK162 (Phase Ib)</measure>
    <time_frame>Cycle 1 Day 1</time_frame>
    <description>To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration-time Profile (AUCtau,ss) of LEE011 (Phase Ib)</measure>
    <time_frame>For the 28-day schedule the steady-state parameter time frame was Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was Cycle 1 Day 14</time_frame>
    <description>To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration-time Profile (AUCtau,ss) of MEK162 (Phase Ib)</measure>
    <time_frame>For the 28-day schedule the steady-state parameter time frame was Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was Cycle 1 Day 14</time_frame>
    <description>To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration-time Profile (Cmin,ss) of LEE011 (Phase Ib)</measure>
    <time_frame>For the 28-day schedule the steady-state parameter time frame was predose on Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was predose on Cycle 1 Day 14</time_frame>
    <description>To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration-time Profile (Cmin,ss) of MEK162 (Phase Ib)</measure>
    <time_frame>For the 28-day schedule the steady-state parameter time frame was predose on Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was predose on Cycle 1 Day 14</time_frame>
    <description>To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration-time Profile (Cmax) of LEE011 (Phase Ib)</measure>
    <time_frame>Cycle 1 Day 1</time_frame>
    <description>To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration-time Profile (Cmax) of MEK162 (Phase Ib)</measure>
    <time_frame>Cycle 1 Day 1</time_frame>
    <description>To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration-time Profile (Cmax,ss) of LEE011 (Phase Ib)</measure>
    <time_frame>For the 28-day schedule the steady-state parameter time frame was Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was Cycle 1 Day 14</time_frame>
    <description>To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration-time Profile (Cmax,ss) of MEK162 (Phase Ib)</measure>
    <time_frame>For the 28-day schedule the steady-state parameter time frame was Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was Cycle 1 Day 14</time_frame>
    <description>To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration-time Profile (Tmax) of LEE011 (Phase Ib)</measure>
    <time_frame>Cycle 1 Day 1</time_frame>
    <description>To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration-time Profile (Tmax) of MEK162 (Phase Ib)</measure>
    <time_frame>Cycle 1 Day 1</time_frame>
    <description>To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration-time Profile (Tmax,ss) of LEE011 (Phase Ib)</measure>
    <time_frame>For the 28-day schedule the steady-state parameter time frame was Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was Cycle 1 Day 14</time_frame>
    <description>To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration-time Profile (Tmax,ss) of MEK162 (Phase Ib)</measure>
    <time_frame>For the 28-day schedule the steady-state parameter time frame was Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was Cycle 1 Day 14</time_frame>
    <description>To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration-time Profile (Accumulation Ratio, Racc_AUC) of LEE011 (Phase Ib)</measure>
    <time_frame>For the 28-day schedule the steady-state parameter time frame was Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was Cycle 1 Day 14</time_frame>
    <description>To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration-time Profile (Accumulation Ratio, Racc_AUC) of MEK162 (Phase Ib)</measure>
    <time_frame>For the 28-day schedule the steady-state parameter time frame was Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was Cycle 1 Day 14</time_frame>
    <description>To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration-time Profile (T1/2,ss) of LEE011 (Phase Ib)</measure>
    <time_frame>For the 28-day schedule the steady-state parameter time frame was Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was Cycle 1 Day 14</time_frame>
    <description>To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration-time Profile (T1/2,ss) of MEK162 (Phase Ib)</measure>
    <time_frame>For the 28-day schedule the steady-state parameter time frame was Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was Cycle 1 Day 14</time_frame>
    <description>To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration-time Profile (CL/F) of LEE011 (Phase Ib)</measure>
    <time_frame>Cycle 1 Day 1</time_frame>
    <description>To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma Concentration-time Profile (CL/F) of MEK162 (Phase Ib)</measure>
    <time_frame>Cycle 1 Day 1</time_frame>
    <description>To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Drug Reactions</measure>
    <time_frame>Approximately 12 months after FPFV</time_frame>
    <description>Safety and tolerability will be characterized through the incidence and severity of adverse drug reactions, serious adverse drug reactions, changes in hematology and chemistry values, vital signs, electrocardiograms (ECGs), dose interruptions, dose reduction and dose intensity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR) - Phase 2</measure>
    <time_frame>Approximately 12 months after the FPFV</time_frame>
    <description>To assess clinical safety as per RECIST 1.1. Evaluation will occur continuously throughout the trial until progression, or death due to underlying cancer.&#xD;
Please note: As clinicaltrials.gov only allows numerical data entry, the value of 999 indicates &quot;not estimable&quot; for confidence interval.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Progression (TTP) - Phase 2</measure>
    <time_frame>Approximately 12 months after the FPFV</time_frame>
    <description>To assess clinical safety as per RECIST 1.1. Evaluation will occur continuously throughout the trial until progression, or death due to underlying cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS) - Phase 1b and Phase 2</measure>
    <time_frame>Approximately 12 months after the FPFV</time_frame>
    <description>To assess clinical safety as per RECIST 1.1. Evaluation will occur continuously throughout the trial until progression, or death due to underlying cancer.&#xD;
In the Phase 1b part, patients were combined for purposes of PFS analyses based on schedule received, since too few patients received any individual dose level to allow for valid PFS estimates within the respective dose levels. This is how the data were analyses and presented for the clinical study report.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) - Phase ll</measure>
    <time_frame>Approximately 12 months after the FPFV</time_frame>
    <description>To assess clinical safety as per RECIST 1.1. Evaluation will occur continuously throughout the trial until progression, or death due to underlying cancer.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response (BOR) - Phase II</measure>
    <time_frame>Approximately 12 months after the FPFV</time_frame>
    <description>To assess clinical safety according to RECIST 1.1. Evaluation will occur continuously throughout the trial until progression, or death due to underlying cancer.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">102</enrollment>
  <condition>Locally Advanced or Metastatic NRAS Mutant Melanoma</condition>
  <arm_group>
    <arm_group_label>Phase Ib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The phase Ib is the dose escalation part where successive cohorts of 3-6 newly enrolled patients receiving various dose pairs considering the recommendation from an adaptive BLRM incorporating the EWOC principle until MTD(s)/RP2D is defined. If multiple alternate dosing schedules are explored in parallel, the allocation of patients will proceed in an alternating fashion. Approximately 40 patients are expected to be treated during the phase Ib part of the study.&#xD;
Dosing Schedule 1: MEK162 administered orally twice daily on a continuous dosing schedule. LEE011 administered orally once daily for 21 days followed by a 1 week break (28-day cycle).&#xD;
Dosing Schedule 2: MEK162 administered orally twice daily and LEE011 administered orally once daily for 3 weeks followed by a 1 week break (28-day cycle).&#xD;
Dosing Schedule 3: MEK162 administered orally twice daily and LEE011 administered once daily for 2 weeks followed by a 1 week break (21-day cycle).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase II</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The Phase II part will begin once the MTD(s)/RP2D have been determined in the Phase Ib in order to assess antitumor activity of the LEE011and MEK162 combination. Patients enrolled in the Phase II part of the study are required to have measurable disease. Approximately 40 patients will be treated in this part.&#xD;
Phase II part will begin at the RP2D on the chosen schedule in order to assess antitumor activity of the LEE011 and MEK162 combination.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LEE011</intervention_name>
    <description>LEE011 will be administered orally once daily</description>
    <arm_group_label>Phase II</arm_group_label>
    <arm_group_label>Phase Ib</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEK162</intervention_name>
    <description>MEK162 will be administered orally twice daily</description>
    <arm_group_label>Phase II</arm_group_label>
    <arm_group_label>Phase Ib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of&#xD;
             0 - 1.&#xD;
&#xD;
          -  Patients enrolled into phase Ib may be enrolled with evaluable disease only. Patients&#xD;
             enrolled into the phase II expansion must have at least one measurable lesion as&#xD;
             defined by RECIST 1.1 criteria for solid tumors.&#xD;
&#xD;
          -  Patients must have adequate organ function, as defined by the following parameter&#xD;
&#xD;
               1. Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L.&#xD;
&#xD;
               2. Hemoglobin (Hgb) ≥ 9 g/dL.&#xD;
&#xD;
               3. Platelets ≥ 75 x 109/L without transfusions within 21 days before 1st treatment.&#xD;
&#xD;
               4. PT/INR and aPTT ≤ 1.5 ULN.&#xD;
&#xD;
               5. Serum creatinine ≤1.5 ULN.&#xD;
&#xD;
               6. Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN).&#xD;
&#xD;
               7. AST and ALT ≤ 3 x ULN, except in patients with tumor involvement of the liver who&#xD;
                  must have AST and ALT ≤ 5 x ULN.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of any brain metastases detected by MRI or CT with i.v. contrast of the brain&#xD;
             at screening.&#xD;
&#xD;
          -  Uncontrolled arterial hypertension despite medical treatment&#xD;
&#xD;
          -  Impaired cardiac function or clinically significant cardiac diseases, including any of&#xD;
             the following:&#xD;
&#xD;
               1. Left ventricular ejection fraction (LVEF) &lt; 50% as determined by multiple gated&#xD;
                  acquisition scan (MUGA) or echocardiogram (ECHO).&#xD;
&#xD;
               2. Congenital long QT syndrome or family history of unexpected sudden cardiac death.&#xD;
&#xD;
               3. QTcF corrected with Frederica's or Bazett's formula QTcB &gt;450 ms for males and&#xD;
                  &gt;470 ms for females on screening ECG.&#xD;
&#xD;
               4. Angina pectoris ≤ 3 months prior to starting study drug&#xD;
&#xD;
               5. Acute myocardial infarction ≤ 3 months prior to starting study drug&#xD;
&#xD;
               6. Clinically significant resting bradycardia&#xD;
&#xD;
               7. History or presence of ventricular tachyarrhythmia&#xD;
&#xD;
               8. Unstable atrial fibrillation (ventricular response &gt;100 bpm)&#xD;
&#xD;
               9. Complete left bundle branch block&#xD;
&#xD;
              10. Right bundle branch block and left anterior hemi block (bifascicular block)&#xD;
&#xD;
              11. Obligate use of a cardiac pacemaker or implantable cardioverter defibrillator&#xD;
&#xD;
              12. Any other clinically significant heart disease&#xD;
&#xD;
          -  Patients who are currently receiving treatment with agents that are known to cause QTc&#xD;
             prolongation in humans.&#xD;
&#xD;
          -  Patients who have neuromuscular disorders that are associated with elevated CK (e.g.,&#xD;
             inflammatory myopathies, muscular dystrophy, amyotrophic lateral sclerosis, spinal&#xD;
             muscular atrophy) or elevated baseline CK levels (≥ Grade 2)&#xD;
&#xD;
          -  Patients who are currently receiving treatment with agents that are metabolized&#xD;
             predominantly through CYP3A4 and that have a narrow therapeutic window.&#xD;
&#xD;
          -  Patients with concurrent severe and/or uncontrolled concurrent medical conditions that&#xD;
             could compromise participation in the study (i.e. uncontrolled diabetes mellitus,&#xD;
             clinically significant pulmonary disease, clinically significant neurological&#xD;
             disorder, active or uncontrolled infection).&#xD;
&#xD;
          -  History or current evidence of retinal vein occlusion (RVO) or current risk factors&#xD;
             for RVO (e.g. uncontrolled glaucoma or ocular hypertension, history of hyperviscosity&#xD;
             or hypercoagulability syndromes).&#xD;
&#xD;
        Other protocol related inclusion/exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, Dept of Oncology</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Pacific Medical Center Onc Dept</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94120-7999</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute Dept of Oncology</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center Dept Oncology</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia University Medical Center- New York Presbyterian Onc Dept.</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center SC - Dept of Oncology .</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas/MD Anderson Cancer Center Dept of Onc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigative Site 1003</name>
      <address>
        <city>North Sydney</city>
        <state>New South Wales</state>
        <zip>2060</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigative Site 1002</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigator Site 1001</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigative Site 1050</name>
      <address>
        <city>Essen</city>
        <zip>45147</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigative Site 1053</name>
      <address>
        <city>Gera</city>
        <zip>07548</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigative Site 1052</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigative Site 1051</name>
      <address>
        <city>Muenchen</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigative Site 1101</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigative Site 1151</name>
      <address>
        <city>Utrecht</city>
        <state>The Netherlands</state>
        <zip>3508 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigative Site 1150</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Norway</country>
  </removed_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>January 24, 2013</study_first_submitted>
  <study_first_submitted_qc>January 30, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 1, 2013</study_first_posted>
  <results_first_submitted>May 6, 2020</results_first_submitted>
  <results_first_submitted_qc>July 24, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 12, 2020</results_first_posted>
  <disposition_first_submitted>December 14, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>December 14, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">December 19, 2018</disposition_first_posted>
  <last_update_submitted>November 23, 2020</last_update_submitted>
  <last_update_submitted_qc>November 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 16, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/72/NCT01781572/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>August 26, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/72/NCT01781572/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Upon study entry, all patients were required to provide either an archival tumor biopsy with the corresponding pathology report or a newly obtained tumor biopsy. Both parts of the study were limited to patients aged 18 or older with metastatic or locally advanced NRAS-mutant melanoma.</recruitment_details>
      <pre_assignment_details>Screening details:&#xD;
Screening assessments were performed within 14 days prior to the first dose of ribociclib and binimetinib except for the pretreatment tumor biopsy, which was performed within 28 days before dosing. A total of 23 patients were screened but not enrolled.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Phase 1b 28-Day Schedule</title>
          <description>A combined total of 61 patients were treated in the 28-day (n=29) and 21-day (n=32) treatment cycles, and all patients discontinued treatment. The starting dose in the 28-day schedule was binimetinib 45 mg BID + ribociclib 200 mg QD.&#xD;
28-Day Schedule: ribociclib was taken QD for 21 consecutive days followed by a 7-day planned break.&#xD;
Binimetinib was taken BID on a continuous dosing schedule.</description>
        </group>
        <group group_id="P2">
          <title>Phase 1b 21-Day Schedule</title>
          <description>A combined total of 61 patients were treated in the 28-day (n=29) and 21-day (n=32) treatment cycles, and all patients discontinued treatment. The starting dose in the 21-day schedule was binimetinib 30 mg BID + ribociclib 200 mg QD.&#xD;
21-Day Schedule: ribociclib QD and binimetinib BID were taken QD for 14 consecutive days followed by a 7-day planned break.</description>
        </group>
        <group group_id="P3">
          <title>Phase 2 (Dose-expansion Phase)</title>
          <description>The dose-expansion phase was initiated with a newly recruited group of patients.&#xD;
A total of 41 patients were treated, and all patients (100%) discontinued treatment. Based on the recommendations of the dose-escalation meetings between the Sponsor and the Investigators, the RP2D and schedule for the combination of binimetinib and ribociclib to be used for the dose-expansion phase of the study was binimetinib 45 mg BID + ribociclib 200 mg QD on the 28-day schedule.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>MEK162 45mg BID+LEE011 200mg</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="41"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive disease</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="23"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>MEK162 45mg BID+LEE011 250mg</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Progressive Disease</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>MEK162 30mg BID+LEE011 300mg</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive Disease</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>MEK162 45mg BID+LEE011 300mg</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive Disease</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>MEK162 30mg LEE011 200mg</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Progressive Disease</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>MEK162 45mg LEE011 450mg</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive Disease</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>MEK162 45mg LEE011 600mg</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Progressive Disease</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The baseline analysis population consists of the Full Analysis Set (FAS), which includes all patients who received at least 1 dose of ribociclib or binimetinib.</population>
      <group_list>
        <group group_id="B1">
          <title>Phase 1b 28-Day MEK162 45mg + LEE011 200mg</title>
          <description>MEK162 45mg + LEE011 200mg</description>
        </group>
        <group group_id="B2">
          <title>Phase 1b 28-Day MEK162 45mg+LEE011 250mg</title>
          <description>MEK162 45mg+LEE011 250mg</description>
        </group>
        <group group_id="B3">
          <title>Phase 1b 28-Day MEK162 30mg+LEE011 300mg</title>
          <description>MEK162 30mg+LEE011 300mg</description>
        </group>
        <group group_id="B4">
          <title>Phase 1b 28-Day MEK162 45mg+LEE011 300mg</title>
          <description>MEK162 45mg+LEE011 300mg</description>
        </group>
        <group group_id="B5">
          <title>Phase 1b 21-Day MEK162 30mg+LEE011 200mg</title>
          <description>MEK162 30mg+LEE011 200mg</description>
        </group>
        <group group_id="B6">
          <title>Phase 1b 21-Day MEK162 45mg+LEE011 200mg</title>
          <description>MEK162 45mg+LEE011 200mg</description>
        </group>
        <group group_id="B7">
          <title>Phase 1b 21-Day MEK162 30mg+LEE011 300mg</title>
          <description>MEK162 30mg+LEE011 300mg</description>
        </group>
        <group group_id="B8">
          <title>Phase 1b 21-Day MEK162 45mg+LEE011 300mg</title>
          <description>MEK162 45mg+LEE011 300mg</description>
        </group>
        <group group_id="B9">
          <title>Phase 1b 21-Day MEK162 45mg+LEE011 450mg</title>
          <description>MEK162 45mg+LEE011 450mg</description>
        </group>
        <group group_id="B10">
          <title>Phase 1b 21-Day MEK162 45mg+LEE011 600mg</title>
          <description>MEK162 45mg+LEE011 600mg</description>
        </group>
        <group group_id="B11">
          <title>Phase 2: MEK162 45mg+LEE011 200mg</title>
          <description>MEK162 45mg+LEE011 200mg</description>
        </group>
        <group group_id="B12">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="4"/>
            <count group_id="B4" value="6"/>
            <count group_id="B5" value="5"/>
            <count group_id="B6" value="6"/>
            <count group_id="B7" value="2"/>
            <count group_id="B8" value="4"/>
            <count group_id="B9" value="9"/>
            <count group_id="B10" value="6"/>
            <count group_id="B11" value="41"/>
            <count group_id="B12" value="102"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="5"/>
                    <measurement group_id="B11" value="19"/>
                    <measurement group_id="B12" value="54"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="5"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="22"/>
                    <measurement group_id="B12" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" spread="14.51"/>
                    <measurement group_id="B2" value="57" spread="9.02"/>
                    <measurement group_id="B3" value="61.5" spread="21.30"/>
                    <measurement group_id="B4" value="56" spread="15.04"/>
                    <measurement group_id="B5" value="63.0" spread="7.50"/>
                    <measurement group_id="B6" value="62.5" spread="12.687"/>
                    <measurement group_id="B7" value="55.0" spread="18.38"/>
                    <measurement group_id="B8" value="63.5" spread="19.48"/>
                    <measurement group_id="B9" value="67.0" spread="8.59"/>
                    <measurement group_id="B10" value="58.5" spread="5.56"/>
                    <measurement group_id="B11" value="65" spread="12.35"/>
                    <measurement group_id="B12" value="61" spread="12.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="5"/>
                    <measurement group_id="B11" value="15"/>
                    <measurement group_id="B12" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="3"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="8"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="26"/>
                    <measurement group_id="B12" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Race</title>
              <category_list>
                <category>
                  <title>Caucasian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="6"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="4"/>
                    <measurement group_id="B9" value="9"/>
                    <measurement group_id="B10" value="6"/>
                    <measurement group_id="B11" value="40"/>
                    <measurement group_id="B12" value="100"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="1"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82.57" spread="15.014"/>
                    <measurement group_id="B2" value="91.47" spread="20.093"/>
                    <measurement group_id="B3" value="71.30" spread="12.631"/>
                    <measurement group_id="B4" value="97.48" spread="35.464"/>
                    <measurement group_id="B5" value="73.66" spread="8.104"/>
                    <measurement group_id="B6" value="85.20" spread="20.733"/>
                    <measurement group_id="B7" value="80.80" spread="15.274"/>
                    <measurement group_id="B8" value="97.20" spread="24.554"/>
                    <measurement group_id="B9" value="92.41" spread="20.709"/>
                    <measurement group_id="B10" value="62.95" spread="6.111"/>
                    <measurement group_id="B11" value="79.63" spread="17.334"/>
                    <measurement group_id="B12" value="83.69" spread="20.621"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <units>(kg)/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.57" spread="5.136"/>
                    <measurement group_id="B2" value="26.84" spread="5.332"/>
                    <measurement group_id="B3" value="25.95" spread="3.347"/>
                    <measurement group_id="B4" value="30.38" spread="9.733"/>
                    <measurement group_id="B5" value="23.85" spread="2.451"/>
                    <measurement group_id="B6" value="27.80" spread="6.185"/>
                    <measurement group_id="B7" value="27.92" spread="7.526"/>
                    <measurement group_id="B8" value="31.71" spread="5.305"/>
                    <measurement group_id="B9" value="28.08" spread="6.594"/>
                    <measurement group_id="B10" value="23.50" spread="3.293"/>
                    <measurement group_id="B11" value="26.69" spread="5.014"/>
                    <measurement group_id="B12" value="27.34" spread="5.841"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>ECOG performance status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>0-Without restriction</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="5"/>
                    <measurement group_id="B7" value="2"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="5"/>
                    <measurement group_id="B10" value="5"/>
                    <measurement group_id="B11" value="28"/>
                    <measurement group_id="B12" value="65"/>
                  </measurement_list>
                </category>
                <category>
                  <title>1-Restricted in physically strenuous activity</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="4"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="2"/>
                    <measurement group_id="B9" value="4"/>
                    <measurement group_id="B10" value="1"/>
                    <measurement group_id="B11" value="13"/>
                    <measurement group_id="B12" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>2-Ambulatory and capable of all selfcare</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Dose Limiting Toxicities (Phase Ib)</title>
        <description>To estimate the maximum tolerate doses (MTDs) and/or identify the RP2D and schedule of LEE011 and MEK162 combination. A dose-limiting toxicity (DLT) was defined as an AE or clinically significant abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurred within the first cycle of treatment with ribociclib and binimetinib.</description>
        <time_frame>first 28 days of treatment</time_frame>
        <population>Analysis is comprised of the dose-determining set, which is all patients from the safety set who either met the minimum exposure criterion below and had sufficient safety evaluations during Cycle 1 or discontinued earlier due to DLT during Cycle 1.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1b 28-Day MEK162 45mg + LEE011 200mg</title>
            <description>MEK162 45mg + LEE011 200mg</description>
          </group>
          <group group_id="O2">
            <title>Phase 1b 28-Day MEK162 45mg+LEE011 250mg</title>
            <description>MEK162 45mg+LEE011 250mg</description>
          </group>
          <group group_id="O3">
            <title>Phase 1b 28-Day MEK162 30mg+LEE011 300mg</title>
            <description>MEK162 30mg+LEE011 300mg</description>
          </group>
          <group group_id="O4">
            <title>Phase 1b 28-Day MEK162 45mg+LEE011 300mg</title>
            <description>MEK162 45mg+LEE011 300mg</description>
          </group>
          <group group_id="O5">
            <title>Phase 1b 21-Day MEK162 30mg+LEE011 200mg</title>
            <description>MEK162 30mg+LEE011 200mg</description>
          </group>
          <group group_id="O6">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 200mg</title>
            <description>MEK162 45mg+LEE011 200mg</description>
          </group>
          <group group_id="O7">
            <title>Phase 1b 21-Day MEK162 30mg+LEE011 300mg</title>
            <description>MEK162 30mg+LEE011 300mg</description>
          </group>
          <group group_id="O8">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 300mg</title>
            <description>MEK162 45mg+LEE011 300mg</description>
          </group>
          <group group_id="O9">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 450mg</title>
            <description>MEK162 45mg+LEE011 450mg</description>
          </group>
          <group group_id="O10">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 600mg</title>
            <description>MEK162 45mg+LEE011 600mg</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Dose Limiting Toxicities (Phase Ib)</title>
          <description>To estimate the maximum tolerate doses (MTDs) and/or identify the RP2D and schedule of LEE011 and MEK162 combination. A dose-limiting toxicity (DLT) was defined as an AE or clinically significant abnormal laboratory value assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurred within the first cycle of treatment with ribociclib and binimetinib.</description>
          <population>Analysis is comprised of the dose-determining set, which is all patients from the safety set who either met the minimum exposure criterion below and had sufficient safety evaluations during Cycle 1 or discontinued earlier due to DLT during Cycle 1.</population>
          <units>occurrence</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="2"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="9"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="1"/>
                    <measurement group_id="O7" value="0"/>
                    <measurement group_id="O8" value="1"/>
                    <measurement group_id="O9" value="2"/>
                    <measurement group_id="O10" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Objective Response Rate (ORR) (Phase II)</title>
        <description>ORR is the proportion of patients with best overall response of complete response (CR) or partial response (PR) by month 2 assessed according to RECIST 1.1 criteria. ORR is done to describe the anti-tumor activity of LEE011 and MEK162 combination. The primary analysis of the ORR was based on the Investigator's assessment of overall lesion responses per RECIST 1.1.</description>
        <time_frame>Approximately 12 months after the FPFV</time_frame>
        <population>Analysis population consist of the Full Analysis Set, which included all patients who received at least one dose of binimetinib or ribociclib and was used for the analysis of all endpoints unless noted otherwise.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Dose Expansion</title>
            <description>binimetinib 45 mg BID + ribociclib 200 mg QD (MEK 45mg + LEE 200mg)</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (ORR) (Phase II)</title>
          <description>ORR is the proportion of patients with best overall response of complete response (CR) or partial response (PR) by month 2 assessed according to RECIST 1.1 criteria. ORR is done to describe the anti-tumor activity of LEE011 and MEK162 combination. The primary analysis of the ORR was based on the Investigator's assessment of overall lesion responses per RECIST 1.1.</description>
          <population>Analysis population consist of the Full Analysis Set, which included all patients who received at least one dose of binimetinib or ribociclib and was used for the analysis of all endpoints unless noted otherwise.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration-time Profile (AUCtau) of LEE011 (Phase Ib)</title>
        <description>To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib).</description>
        <time_frame>Cycle 1 Day 1</time_frame>
        <population>Analysis population consist of the pharmacokinetic analysis set (PAS) which consisted of all patients who had at least one blood sample providing evaluable PK data and received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1b 28-Day MEK162 45mg + LEE011 200mg</title>
            <description>MEK162 45mg + LEE011 200mg</description>
          </group>
          <group group_id="O2">
            <title>Phase 1b 28-Day MEK162 45mg+LEE011 250mg</title>
            <description>MEK162 45mg+LEE011 250mg</description>
          </group>
          <group group_id="O3">
            <title>Phase 1b 28-Day MEK162 30mg+LEE011 300mg</title>
            <description>MEK162 30mg+LEE011 300mg</description>
          </group>
          <group group_id="O4">
            <title>Phase 1b 28-Day MEK162 45mg+LEE011 300mg</title>
            <description>MEK162 45mg+LEE011 300mg</description>
          </group>
          <group group_id="O5">
            <title>Phase 1b 21-Day MEK162 30mg+LEE011 200mg</title>
            <description>MEK162 30mg+LEE011 200mg</description>
          </group>
          <group group_id="O6">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 200mg</title>
            <description>MEK162 45mg+LEE011 200mg</description>
          </group>
          <group group_id="O7">
            <title>Phase 1b 21-Day MEK162 30mg+LEE011 300mg</title>
            <description>MEK162 30mg+LEE011 300mg</description>
          </group>
          <group group_id="O8">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 300mg</title>
            <description>MEK162 45mg+LEE011 300mg</description>
          </group>
          <group group_id="O9">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 450mg</title>
            <description>MEK162 45mg+LEE011 450mg</description>
          </group>
          <group group_id="O10">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 600mg</title>
            <description>MEK162 45mg+LEE011 600mg</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration-time Profile (AUCtau) of LEE011 (Phase Ib)</title>
          <description>To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib).</description>
          <population>Analysis population consist of the pharmacokinetic analysis set (PAS) which consisted of all patients who had at least one blood sample providing evaluable PK data and received at least one dose of study drug.</population>
          <units>h*ng/ml</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="1"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="9"/>
                <count group_id="O10" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2120" spread="66.2"/>
                    <measurement group_id="O2" value="3020" spread="99.4"/>
                    <measurement group_id="O3" value="5280" spread="27.8"/>
                    <measurement group_id="O4" value="3860" spread="42.3"/>
                    <measurement group_id="O5" value="2340" spread="113"/>
                    <measurement group_id="O6" value="2230" spread="74.5"/>
                    <measurement group_id="O7" value="5020" spread="NA">Insufficient number of participants to calculate.</measurement>
                    <measurement group_id="O8" value="2960" spread="46.4"/>
                    <measurement group_id="O9" value="5550" spread="50.3"/>
                    <measurement group_id="O10" value="9840" spread="65.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration-time Profile (AUCtau) of MEK162 (Phase Ib)</title>
        <description>To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib).</description>
        <time_frame>Cycle 1 Day 1</time_frame>
        <population>The analysis group is comprised of the pharmacokinetic analysis set (PAS) consisted of all patients who had at least one blood sample providing evaluable PK data and received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1b 28-Day MEK162 45mg + LEE011 200mg</title>
            <description>MEK162 45mg + LEE011 200mg</description>
          </group>
          <group group_id="O2">
            <title>Phase 1b 28-Day MEK162 45mg+LEE011 250mg</title>
            <description>MEK162 45mg+LEE011 250mg</description>
          </group>
          <group group_id="O3">
            <title>Phase 1b 28-Day MEK162 30mg+LEE011 300mg</title>
            <description>MEK162 30mg+LEE011 300mg</description>
          </group>
          <group group_id="O4">
            <title>Phase 1b 28-Day MEK162 45mg+LEE011 300mg</title>
            <description>MEK162 45mg+LEE011 300mg</description>
          </group>
          <group group_id="O5">
            <title>Phase 1b 21-Day MEK162 30mg+LEE011 200mg</title>
            <description>MEK162 30mg+LEE011 200mg</description>
          </group>
          <group group_id="O6">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 200mg</title>
            <description>MEK162 45mg+LEE011 200mg</description>
          </group>
          <group group_id="O7">
            <title>Phase 1b 21-Day MEK162 30mg+LEE011 300mg</title>
            <description>MEK162 30mg+LEE011 300mg</description>
          </group>
          <group group_id="O8">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 300mg</title>
            <description>MEK162 45mg+LEE011 300mg</description>
          </group>
          <group group_id="O9">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 450mg</title>
            <description>MEK162 45mg+LEE011 450mg</description>
          </group>
          <group group_id="O10">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 600mg</title>
            <description>MEK162 45mg+LEE011 600mg</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration-time Profile (AUCtau) of MEK162 (Phase Ib)</title>
          <description>To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib).</description>
          <population>The analysis group is comprised of the pharmacokinetic analysis set (PAS) consisted of all patients who had at least one blood sample providing evaluable PK data and received at least one dose of study drug.</population>
          <units>h*ng/ml</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="2"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="2"/>
                <count group_id="O8" value="1"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1310" spread="36.8"/>
                    <measurement group_id="O2" value="1070" spread="NA">Insufficient number of participants to calculate.</measurement>
                    <measurement group_id="O3" value="1640" spread="NA">Insufficient number of participants to calculate.</measurement>
                    <measurement group_id="O4" value="1240" spread="NA">Insufficient number of participants to calculate.</measurement>
                    <measurement group_id="O5" value="1610" spread="76"/>
                    <measurement group_id="O6" value="1820" spread="82.1"/>
                    <measurement group_id="O7" value="747" spread="31.8"/>
                    <measurement group_id="O8" value="2740" spread="NA">Insufficient number of participants to calculate.</measurement>
                    <measurement group_id="O9" value="2110" spread="44.2"/>
                    <measurement group_id="O10" value="4060" spread="NA">Insufficient number of participants to calculate.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration-time Profile (AUCtau,ss) of LEE011 (Phase Ib)</title>
        <description>To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib).</description>
        <time_frame>For the 28-day schedule the steady-state parameter time frame was Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was Cycle 1 Day 14</time_frame>
        <population>The analysis group is comprised of the pharmacokinetic analysis set (PAS) consisted of all patients who had at least one blood sample providing evaluable PK data and received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1b 28-Day MEK162 45mg + LEE011 200mg</title>
            <description>MEK162 45mg + LEE011 200mg</description>
          </group>
          <group group_id="O2">
            <title>Phase 1b 28-Day MEK162 45mg+LEE011 250mg</title>
            <description>MEK162 45mg+LEE011 250mg</description>
          </group>
          <group group_id="O3">
            <title>Phase 1b 28-Day MEK162 30mg+LEE011 300mg</title>
            <description>MEK162 30mg+LEE011 300mg</description>
          </group>
          <group group_id="O4">
            <title>Phase 1b 28-Day MEK162 45mg+LEE011 300mg</title>
            <description>MEK162 45mg+LEE011 300mg</description>
          </group>
          <group group_id="O5">
            <title>Phase 1b 21-Day MEK162 30mg+LEE011 200mg</title>
            <description>MEK162 30mg+LEE011 200mg</description>
          </group>
          <group group_id="O6">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 200mg</title>
            <description>MEK162 45mg+LEE011 200mg</description>
          </group>
          <group group_id="O7">
            <title>Phase 1b 21-Day MEK162 30mg+LEE011 300mg</title>
            <description>MEK162 30mg+LEE011 300mg</description>
          </group>
          <group group_id="O8">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 300mg</title>
            <description>MEK162 45mg+LEE011 300mg</description>
          </group>
          <group group_id="O9">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 450mg</title>
            <description>MEK162 45mg+LEE011 450mg</description>
          </group>
          <group group_id="O10">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 600mg</title>
            <description>MEK162 45mg+LEE011 600mg</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration-time Profile (AUCtau,ss) of LEE011 (Phase Ib)</title>
          <description>To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib).</description>
          <population>The analysis group is comprised of the pharmacokinetic analysis set (PAS) consisted of all patients who had at least one blood sample providing evaluable PK data and received at least one dose of study drug.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="2"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="2"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="5"/>
                <count group_id="O10" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3080" spread="63.2"/>
                    <measurement group_id="O2" value="15000" spread="NA">Insufficient number of participants to calculate.</measurement>
                    <measurement group_id="O3" value="8650" spread="NA">Insufficient number of participants to calculate.</measurement>
                    <measurement group_id="O4" value="7050" spread="41.3"/>
                    <measurement group_id="O5" value="4700" spread="28.9"/>
                    <measurement group_id="O6" value="4370" spread="60.3"/>
                    <measurement group_id="O7" value="7480" spread="2.89"/>
                    <measurement group_id="O8" value="9570" spread="50.5"/>
                    <measurement group_id="O9" value="11100" spread="29.1"/>
                    <measurement group_id="O10" value="30700" spread="46.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration-time Profile (AUCtau,ss) of MEK162 (Phase Ib)</title>
        <description>To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib).</description>
        <time_frame>For the 28-day schedule the steady-state parameter time frame was Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was Cycle 1 Day 14</time_frame>
        <population>The analysis group is comprised of the pharmacokinetic analysis set (PAS) consisted of all patients who had at least one blood sample providing evaluable PK data and received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1b 28-Day MEK162 45mg + LEE011 200mg</title>
            <description>MEK162 45mg + LEE011 200mg</description>
          </group>
          <group group_id="O2">
            <title>Phase 1b 28-Day MEK162 45mg+LEE011 250mg</title>
            <description>MEK162 45mg+LEE011 250mg</description>
          </group>
          <group group_id="O3">
            <title>Phase 1b 28-Day MEK162 30mg+LEE011 300mg</title>
            <description>MEK162 30mg+LEE011 300mg</description>
          </group>
          <group group_id="O4">
            <title>Phase 1b 28-Day MEK162 45mg+LEE011 300mg</title>
            <description>MEK162 45mg+LEE011 300mg</description>
          </group>
          <group group_id="O5">
            <title>Phase 1b 21-Day MEK162 30mg+LEE011 200mg</title>
            <description>MEK162 30mg+LEE011 200mg</description>
          </group>
          <group group_id="O6">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 200mg</title>
            <description>MEK162 45mg+LEE011 200mg</description>
          </group>
          <group group_id="O7">
            <title>Phase 1b 21-Day MEK162 30mg+LEE011 300mg</title>
            <description>MEK162 30mg+LEE011 300mg</description>
          </group>
          <group group_id="O8">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 300mg</title>
            <description>MEK162 45mg+LEE011 300mg</description>
          </group>
          <group group_id="O9">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 450mg</title>
            <description>MEK162 45mg+LEE011 450mg</description>
          </group>
          <group group_id="O10">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 600mg</title>
            <description>MEK162 45mg+LEE011 600mg</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration-time Profile (AUCtau,ss) of MEK162 (Phase Ib)</title>
          <description>To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib).</description>
          <population>The analysis group is comprised of the pharmacokinetic analysis set (PAS) consisted of all patients who had at least one blood sample providing evaluable PK data and received at least one dose of study drug.</population>
          <units>h*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="2"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="4"/>
                <count group_id="O10" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2250" spread="37.7"/>
                    <measurement group_id="O2" value="2450" spread="NA">Insufficient number of participants to calculate.</measurement>
                    <measurement group_id="O4" value="1540" spread="30.0"/>
                    <measurement group_id="O5" value="2180" spread="12.1"/>
                    <measurement group_id="O6" value="2980" spread="58.9"/>
                    <measurement group_id="O7" value="1990" spread="22.2"/>
                    <measurement group_id="O8" value="3680" spread="40.9"/>
                    <measurement group_id="O9" value="2840" spread="57.5"/>
                    <measurement group_id="O10" value="3340" spread="86.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration-time Profile (Cmin,ss) of LEE011 (Phase Ib)</title>
        <description>To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib).</description>
        <time_frame>For the 28-day schedule the steady-state parameter time frame was predose on Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was predose on Cycle 1 Day 14</time_frame>
        <population>Analysis population consist of the pharmacokinetic analysis set (PAS), which consisted of all patients who had at least one blood sample providing evaluable PK data and received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1b 28-Day MEK162 45mg + LEE011 200mg</title>
            <description>MEK162 45mg + LEE011 200mg</description>
          </group>
          <group group_id="O2">
            <title>Phase 1b 28-Day MEK162 45mg+LEE011 250mg</title>
            <description>MEK162 45mg+LEE011 250mg</description>
          </group>
          <group group_id="O3">
            <title>Phase 1b 28-Day MEK162 30mg+LEE011 300mg</title>
            <description>MEK162 30mg+LEE011 300mg</description>
          </group>
          <group group_id="O4">
            <title>Phase 1b 28-Day MEK162 45mg+LEE011 300mg</title>
            <description>MEK162 45mg+LEE011 300mg</description>
          </group>
          <group group_id="O5">
            <title>Phase 1b 21-Day MEK162 30mg+LEE011 200mg</title>
            <description>MEK162 30mg+LEE011 200mg</description>
          </group>
          <group group_id="O6">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 200mg</title>
            <description>MEK162 45mg+LEE011 200mg</description>
          </group>
          <group group_id="O7">
            <title>Phase 1b 21-Day MEK162 30mg+LEE011 300mg</title>
            <description>MEK162 30mg+LEE011 300mg</description>
          </group>
          <group group_id="O8">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 300mg</title>
            <description>MEK162 45mg+LEE011 300mg</description>
          </group>
          <group group_id="O9">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 450mg</title>
            <description>MEK162 45mg+LEE011 450mg</description>
          </group>
          <group group_id="O10">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 600mg</title>
            <description>MEK162 45mg+LEE011 600mg</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration-time Profile (Cmin,ss) of LEE011 (Phase Ib)</title>
          <description>To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib).</description>
          <population>Analysis population consist of the pharmacokinetic analysis set (PAS), which consisted of all patients who had at least one blood sample providing evaluable PK data and received at least one dose of study drug.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="2"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="5"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.1" spread="56.3"/>
                    <measurement group_id="O2" value="256" spread="79.8"/>
                    <measurement group_id="O3" value="220" spread="NA">Insufficient number of participants to calculate.</measurement>
                    <measurement group_id="O4" value="113" spread="56.4"/>
                    <measurement group_id="O5" value="117" spread="39.8"/>
                    <measurement group_id="O6" value="97.6" spread="77.8"/>
                    <measurement group_id="O7" value="140" spread="25.6"/>
                    <measurement group_id="O8" value="216" spread="7.88"/>
                    <measurement group_id="O9" value="264" spread="44.9"/>
                    <measurement group_id="O10" value="570" spread="91.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration-time Profile (Cmin,ss) of MEK162 (Phase Ib)</title>
        <description>To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib).</description>
        <time_frame>For the 28-day schedule the steady-state parameter time frame was predose on Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was predose on Cycle 1 Day 14</time_frame>
        <population>Analysis population consist of the pharmacokinetic analysis set (PAS), which consisted of all patients who had at least one blood sample providing evaluable PK data and received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1b 28-Day MEK162 45mg + LEE011 200mg</title>
            <description>MEK162 45mg + LEE011 200mg</description>
          </group>
          <group group_id="O2">
            <title>Phase 1b 28-Day MEK162 45mg+LEE011 250mg</title>
            <description>MEK162 45mg+LEE011 250mg</description>
          </group>
          <group group_id="O3">
            <title>Phase 1b 28-Day MEK162 30mg+LEE011 300mg</title>
            <description>MEK162 30mg+LEE011 300mg</description>
          </group>
          <group group_id="O4">
            <title>Phase 1b 28-Day MEK162 45mg+LEE011 300mg</title>
            <description>MEK162 45mg+LEE011 300mg</description>
          </group>
          <group group_id="O5">
            <title>Phase 1b 21-Day MEK162 30mg+LEE011 200mg</title>
            <description>MEK162 30mg+LEE011 200mg</description>
          </group>
          <group group_id="O6">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 200mg</title>
            <description>MEK162 45mg+LEE011 200mg</description>
          </group>
          <group group_id="O7">
            <title>Phase 1b 21-Day MEK162 30mg+LEE011 300mg</title>
            <description>MEK162 30mg+LEE011 300mg</description>
          </group>
          <group group_id="O8">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 300mg</title>
            <description>MEK162 45mg+LEE011 300mg</description>
          </group>
          <group group_id="O9">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 450mg</title>
            <description>MEK162 45mg+LEE011 450mg</description>
          </group>
          <group group_id="O10">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 600mg</title>
            <description>MEK162 45mg+LEE011 600mg</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration-time Profile (Cmin,ss) of MEK162 (Phase Ib)</title>
          <description>To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib).</description>
          <population>Analysis population consist of the pharmacokinetic analysis set (PAS), which consisted of all patients who had at least one blood sample providing evaluable PK data and received at least one dose of study drug.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="1"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="4"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.2" spread="75.4"/>
                    <measurement group_id="O2" value="188" spread="73.9"/>
                    <measurement group_id="O3" value="84.2" spread="NA">Insufficient number of participants to calculate.</measurement>
                    <measurement group_id="O4" value="43.9" spread="60.7"/>
                    <measurement group_id="O5" value="103" spread="31.4"/>
                    <measurement group_id="O6" value="90.4" spread="20.0"/>
                    <measurement group_id="O7" value="123" spread="NA">Insufficient number of participants to calculate.</measurement>
                    <measurement group_id="O8" value="178" spread="38.1"/>
                    <measurement group_id="O9" value="63.9" spread="94.3"/>
                    <measurement group_id="O10" value="179" spread="98.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration-time Profile (Cmax) of LEE011 (Phase Ib)</title>
        <description>To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib).</description>
        <time_frame>Cycle 1 Day 1</time_frame>
        <population>The analysis group is comprised of the pharmacokinetic analysis set (PAS) consisted of all patients who had at least one blood sample providing evaluable PK data and received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1b 28-Day MEK162 45mg + LEE011 200mg</title>
            <description>MEK162 45mg + LEE011 200mg</description>
          </group>
          <group group_id="O2">
            <title>Phase 1b 28-Day MEK162 45mg+LEE011 250mg</title>
            <description>MEK162 45mg+LEE011 250mg</description>
          </group>
          <group group_id="O3">
            <title>Phase 1b 28-Day MEK162 30mg+LEE011 300mg</title>
            <description>MEK162 30mg+LEE011 300mg</description>
          </group>
          <group group_id="O4">
            <title>Phase 1b 28-Day MEK162 45mg+LEE011 300mg</title>
            <description>MEK162 45mg+LEE011 300mg</description>
          </group>
          <group group_id="O5">
            <title>Phase 1b 21-Day MEK162 30mg+LEE011 200mg</title>
            <description>MEK162 30mg+LEE011 200mg</description>
          </group>
          <group group_id="O6">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 200mg</title>
            <description>MEK162 45mg+LEE011 200mg</description>
          </group>
          <group group_id="O7">
            <title>Phase 1b 21-Day MEK162 30mg+LEE011 300mg</title>
            <description>MEK162 30mg+LEE011 300mg</description>
          </group>
          <group group_id="O8">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 300mg</title>
            <description>MEK162 45mg+LEE011 300mg</description>
          </group>
          <group group_id="O9">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 450mg</title>
            <description>MEK162 45mg+LEE011 450mg</description>
          </group>
          <group group_id="O10">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 600mg</title>
            <description>MEK162 45mg+LEE011 600mg</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration-time Profile (Cmax) of LEE011 (Phase Ib)</title>
          <description>To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib).</description>
          <population>The analysis group is comprised of the pharmacokinetic analysis set (PAS) consisted of all patients who had at least one blood sample providing evaluable PK data and received at least one dose of study drug.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="1"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="9"/>
                <count group_id="O10" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="217" spread="90.5"/>
                    <measurement group_id="O2" value="271" spread="87.4"/>
                    <measurement group_id="O3" value="555" spread="44.4"/>
                    <measurement group_id="O4" value="374" spread="47.9"/>
                    <measurement group_id="O5" value="236" spread="143"/>
                    <measurement group_id="O6" value="229" spread="86.0"/>
                    <measurement group_id="O7" value="368" spread="NA">Insufficient number of participants to calculate.</measurement>
                    <measurement group_id="O8" value="307" spread="33.0"/>
                    <measurement group_id="O9" value="506" spread="65.6"/>
                    <measurement group_id="O10" value="1030" spread="54.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration-time Profile (Cmax) of MEK162 (Phase Ib)</title>
        <description>To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib).</description>
        <time_frame>Cycle 1 Day 1</time_frame>
        <population>The analysis group is comprised of the pharmacokinetic analysis set (PAS) consisted of all patients who had at least one blood sample providing evaluable PK data and received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1b 28-Day MEK162 45mg + LEE011 200mg</title>
            <description>MEK162 45mg + LEE011 200mg</description>
          </group>
          <group group_id="O2">
            <title>Phase 1b 28-Day MEK162 45mg+LEE011 250mg</title>
            <description>MEK162 45mg+LEE011 250mg</description>
          </group>
          <group group_id="O3">
            <title>Phase 1b 28-Day MEK162 30mg+LEE011 300mg</title>
            <description>MEK162 30mg+LEE011 300mg</description>
          </group>
          <group group_id="O4">
            <title>Phase 1b 28-Day MEK162 45mg+LEE011 300mg</title>
            <description>MEK162 45mg+LEE011 300mg</description>
          </group>
          <group group_id="O5">
            <title>Phase 1b 21-Day MEK162 30mg+LEE011 200mg</title>
            <description>MEK162 30mg+LEE011 200mg</description>
          </group>
          <group group_id="O6">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 200mg</title>
            <description>MEK162 45mg+LEE011 200mg</description>
          </group>
          <group group_id="O7">
            <title>Phase 1b 21-Day MEK162 30mg+LEE011 300mg</title>
            <description>MEK162 30mg+LEE011 300mg</description>
          </group>
          <group group_id="O8">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 300mg</title>
            <description>MEK162 45mg+LEE011 300mg</description>
          </group>
          <group group_id="O9">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 450mg</title>
            <description>MEK162 45mg+LEE011 450mg</description>
          </group>
          <group group_id="O10">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 600mg</title>
            <description>MEK162 45mg+LEE011 600mg</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration-time Profile (Cmax) of MEK162 (Phase Ib)</title>
          <description>To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib).</description>
          <population>The analysis group is comprised of the pharmacokinetic analysis set (PAS) consisted of all patients who had at least one blood sample providing evaluable PK data and received at least one dose of study drug.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="2"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="9"/>
                <count group_id="O10" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="315" spread="55.7"/>
                    <measurement group_id="O2" value="296" spread="48.4"/>
                    <measurement group_id="O3" value="247" spread="59.7"/>
                    <measurement group_id="O4" value="231" spread="47.3"/>
                    <measurement group_id="O5" value="234" spread="73.9"/>
                    <measurement group_id="O6" value="453" spread="67.1"/>
                    <measurement group_id="O7" value="163" spread="47.8"/>
                    <measurement group_id="O8" value="396" spread="52.7"/>
                    <measurement group_id="O9" value="385" spread="50.3"/>
                    <measurement group_id="O10" value="402" spread="69.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration-time Profile (Cmax,ss) of LEE011 (Phase Ib)</title>
        <description>To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib).</description>
        <time_frame>For the 28-day schedule the steady-state parameter time frame was Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was Cycle 1 Day 14</time_frame>
        <population>The analysis group is comprised of the pharmacokinetic analysis set (PAS) consisted of all patients who had at least one blood sample providing evaluable PK data and received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1b 28-Day MEK162 45mg + LEE011 200mg</title>
            <description>MEK162 45mg + LEE011 200mg</description>
          </group>
          <group group_id="O2">
            <title>Phase 1b 28-Day MEK162 45mg+LEE011 250mg</title>
            <description>MEK162 45mg+LEE011 250mg</description>
          </group>
          <group group_id="O3">
            <title>Phase 1b 28-Day MEK162 30mg+LEE011 300mg</title>
            <description>MEK162 30mg+LEE011 300mg</description>
          </group>
          <group group_id="O4">
            <title>Phase 1b 28-Day MEK162 45mg+LEE011 300mg</title>
            <description>MEK162 45mg+LEE011 300mg</description>
          </group>
          <group group_id="O5">
            <title>Phase 1b 21-Day MEK162 30mg+LEE011 200mg</title>
            <description>MEK162 30mg+LEE011 200mg</description>
          </group>
          <group group_id="O6">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 200mg</title>
            <description>MEK162 45mg+LEE011 200mg</description>
          </group>
          <group group_id="O7">
            <title>Phase 1b 21-Day MEK162 30mg+LEE011 300mg</title>
            <description>MEK162 30mg+LEE011 300mg</description>
          </group>
          <group group_id="O8">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 300mg</title>
            <description>MEK162 45mg+LEE011 300mg</description>
          </group>
          <group group_id="O9">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 450mg</title>
            <description>MEK162 45mg+LEE011 450mg</description>
          </group>
          <group group_id="O10">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 600mg</title>
            <description>MEK162 45mg+LEE011 600mg</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration-time Profile (Cmax,ss) of LEE011 (Phase Ib)</title>
          <description>To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib).</description>
          <population>The analysis group is comprised of the pharmacokinetic analysis set (PAS) consisted of all patients who had at least one blood sample providing evaluable PK data and received at least one dose of study drug.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="2"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="5"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="220" spread="76.5"/>
                    <measurement group_id="O2" value="343" spread="150"/>
                    <measurement group_id="O3" value="220" spread="NA">Insufficient number of participants to calculate.</measurement>
                    <measurement group_id="O4" value="530" spread="30.6"/>
                    <measurement group_id="O5" value="373" spread="62.4"/>
                    <measurement group_id="O6" value="341" spread="69.0"/>
                    <measurement group_id="O7" value="543" spread="11.9"/>
                    <measurement group_id="O8" value="747" spread="33.0"/>
                    <measurement group_id="O9" value="727" spread="34.7"/>
                    <measurement group_id="O10" value="1910" spread="38.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration-time Profile (Cmax,ss) of MEK162 (Phase Ib)</title>
        <description>To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib).</description>
        <time_frame>For the 28-day schedule the steady-state parameter time frame was Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was Cycle 1 Day 14</time_frame>
        <population>The analysis group is comprised of the pharmacokinetic analysis set (PAS) consisted of all patients who had at least one blood sample providing evaluable PK data and received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1b 28-Day MEK162 45mg + LEE011 200mg</title>
            <description>MEK162 45mg + LEE011 200mg</description>
          </group>
          <group group_id="O2">
            <title>Phase 1b 28-Day MEK162 45mg+LEE011 250mg</title>
            <description>MEK162 45mg+LEE011 250mg</description>
          </group>
          <group group_id="O3">
            <title>Phase 1b 28-Day MEK162 30mg+LEE011 300mg</title>
            <description>MEK162 30mg+LEE011 300mg</description>
          </group>
          <group group_id="O4">
            <title>Phase 1b 28-Day MEK162 45mg+LEE011 300mg</title>
            <description>MEK162 45mg+LEE011 300mg</description>
          </group>
          <group group_id="O5">
            <title>Phase 1b 21-Day MEK162 30mg+LEE011 200mg</title>
            <description>MEK162 30mg+LEE011 200mg</description>
          </group>
          <group group_id="O6">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 200mg</title>
            <description>MEK162 45mg+LEE011 200mg</description>
          </group>
          <group group_id="O7">
            <title>Phase 1b 21-Day MEK162 30mg+LEE011 300mg</title>
            <description>MEK162 30mg+LEE011 300mg</description>
          </group>
          <group group_id="O8">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 300mg</title>
            <description>MEK162 45mg+LEE011 300mg</description>
          </group>
          <group group_id="O9">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 450mg</title>
            <description>MEK162 45mg+LEE011 450mg</description>
          </group>
          <group group_id="O10">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 600mg</title>
            <description>MEK162 45mg+LEE011 600mg</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration-time Profile (Cmax,ss) of MEK162 (Phase Ib)</title>
          <description>To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib).</description>
          <population>The analysis group is comprised of the pharmacokinetic analysis set (PAS) consisted of all patients who had at least one blood sample providing evaluable PK data and received at least one dose of study drug.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="2"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="4"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="441" spread="52.6"/>
                    <measurement group_id="O2" value="309" spread="1.60"/>
                    <measurement group_id="O4" value="284" spread="14.5"/>
                    <measurement group_id="O5" value="376" spread="18.0"/>
                    <measurement group_id="O6" value="444" spread="36.6"/>
                    <measurement group_id="O7" value="367" spread="31.5"/>
                    <measurement group_id="O8" value="590" spread="12.3"/>
                    <measurement group_id="O9" value="452" spread="59.2"/>
                    <measurement group_id="O10" value="471" spread="75.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration-time Profile (Tmax) of LEE011 (Phase Ib)</title>
        <description>To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib).</description>
        <time_frame>Cycle 1 Day 1</time_frame>
        <population>Analysis population consist of the pharmacokinetic analysis set (PAS), which consisted of all patients who had at least one blood sample providing evaluable PK data and received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1b 28-Day MEK162 45mg + LEE011 200mg</title>
            <description>MEK162 45mg + LEE011 200mg</description>
          </group>
          <group group_id="O2">
            <title>Phase 1b 28-Day MEK162 45mg+LEE011 250mg</title>
            <description>MEK162 45mg+LEE011 250mg</description>
          </group>
          <group group_id="O3">
            <title>Phase 1b 28-Day MEK162 30mg+LEE011 300mg</title>
            <description>MEK162 30mg+LEE011 300mg</description>
          </group>
          <group group_id="O4">
            <title>Phase 1b 28-Day MEK162 45mg+LEE011 300mg</title>
            <description>MEK162 45mg+LEE011 300mg</description>
          </group>
          <group group_id="O5">
            <title>Phase 1b 21-Day MEK162 30mg+LEE011 200mg</title>
            <description>MEK162 30mg+LEE011 200mg</description>
          </group>
          <group group_id="O6">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 200mg</title>
            <description>MEK162 45mg+LEE011 200mg</description>
          </group>
          <group group_id="O7">
            <title>Phase 1b 21-Day MEK162 30mg+LEE011 300mg</title>
            <description>MEK162 30mg+LEE011 300mg</description>
          </group>
          <group group_id="O8">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 300mg</title>
            <description>MEK162 45mg+LEE011 300mg</description>
          </group>
          <group group_id="O9">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 450mg</title>
            <description>MEK162 45mg+LEE011 450mg</description>
          </group>
          <group group_id="O10">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 600mg</title>
            <description>MEK162 45mg+LEE011 600mg</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration-time Profile (Tmax) of LEE011 (Phase Ib)</title>
          <description>To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib).</description>
          <population>Analysis population consist of the pharmacokinetic analysis set (PAS), which consisted of all patients who had at least one blood sample providing evaluable PK data and received at least one dose of study drug.</population>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="1"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="9"/>
                <count group_id="O10" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.12" lower_limit="1.00" upper_limit="24.92"/>
                    <measurement group_id="O2" value="3.75" lower_limit="2.12" upper_limit="4.10"/>
                    <measurement group_id="O3" value="2.98" lower_limit="0.67" upper_limit="4.08"/>
                    <measurement group_id="O4" value="1.50" lower_limit="0.52" upper_limit="4.00"/>
                    <measurement group_id="O5" value="2.98" lower_limit="1.98" upper_limit="7.95"/>
                    <measurement group_id="O6" value="1.12" lower_limit="0.87" upper_limit="3.83"/>
                    <measurement group_id="O7" value="4.22" lower_limit="4.22" upper_limit="4.22"/>
                    <measurement group_id="O8" value="1.50" lower_limit="1.00" upper_limit="8.00"/>
                    <measurement group_id="O9" value="2.13" lower_limit="1.00" upper_limit="4.03"/>
                    <measurement group_id="O10" value="2.03" lower_limit="1.62" upper_limit="2.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration-time Profile (Tmax) of MEK162 (Phase Ib)</title>
        <description>To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib).</description>
        <time_frame>Cycle 1 Day 1</time_frame>
        <population>Analysis population consist of the pharmacokinetic analysis set (PAS), which consisted of all patients who had at least one blood sample providing evaluable PK data and received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1b 28-Day MEK162 45mg + LEE011 200mg</title>
            <description>MEK162 45mg + LEE011 200mg</description>
          </group>
          <group group_id="O2">
            <title>Phase 1b 28-Day MEK162 45mg+LEE011 250mg</title>
            <description>MEK162 45mg+LEE011 250mg</description>
          </group>
          <group group_id="O3">
            <title>Phase 1b 28-Day MEK162 30mg+LEE011 300mg</title>
            <description>MEK162 30mg+LEE011 300mg</description>
          </group>
          <group group_id="O4">
            <title>Phase 1b 28-Day MEK162 45mg+LEE011 300mg</title>
            <description>MEK162 45mg+LEE011 300mg</description>
          </group>
          <group group_id="O5">
            <title>Phase 1b 21-Day MEK162 30mg+LEE011 200mg</title>
            <description>MEK162 30mg+LEE011 200mg</description>
          </group>
          <group group_id="O6">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 200mg</title>
            <description>MEK162 45mg+LEE011 200mg</description>
          </group>
          <group group_id="O7">
            <title>Phase 1b 21-Day MEK162 30mg+LEE011 300mg</title>
            <description>MEK162 30mg+LEE011 300mg</description>
          </group>
          <group group_id="O8">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 300mg</title>
            <description>MEK162 45mg+LEE011 300mg</description>
          </group>
          <group group_id="O9">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 450mg</title>
            <description>MEK162 45mg+LEE011 450mg</description>
          </group>
          <group group_id="O10">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 600mg</title>
            <description>MEK162 45mg+LEE011 600mg</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration-time Profile (Tmax) of MEK162 (Phase Ib)</title>
          <description>To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib).</description>
          <population>Analysis population consist of the pharmacokinetic analysis set (PAS), which consisted of all patients who had at least one blood sample providing evaluable PK data and received at least one dose of study drug.</population>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="2"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="9"/>
                <count group_id="O10" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.08" lower_limit="0.85" upper_limit="8.00"/>
                    <measurement group_id="O2" value="2.05" lower_limit="0.50" upper_limit="2.12"/>
                    <measurement group_id="O3" value="1.02" lower_limit="1.00" upper_limit="1.97"/>
                    <measurement group_id="O4" value="2.00" lower_limit=".52" upper_limit="4.00"/>
                    <measurement group_id="O5" value="1.98" lower_limit="0.43" upper_limit="7.95"/>
                    <measurement group_id="O6" value="1.11" lower_limit="0.87" upper_limit="2.05"/>
                    <measurement group_id="O7" value="0.76" lower_limit="0.52" upper_limit="1.00"/>
                    <measurement group_id="O8" value="2.00" lower_limit="1.00" upper_limit="4.15"/>
                    <measurement group_id="O9" value="2.17" lower_limit="1.00" upper_limit="8.08"/>
                    <measurement group_id="O10" value="1.17" lower_limit="0.47" upper_limit="4.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration-time Profile (Tmax,ss) of LEE011 (Phase Ib)</title>
        <description>To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib).</description>
        <time_frame>For the 28-day schedule the steady-state parameter time frame was Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was Cycle 1 Day 14</time_frame>
        <population>Analysis population consist of the pharmacokinetic analysis set (PAS), which consisted of all patients who had at least one blood sample providing evaluable PK data and received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1b 28-Day MEK162 45mg + LEE011 200mg</title>
            <description>MEK162 45mg + LEE011 200mg</description>
          </group>
          <group group_id="O2">
            <title>Phase 1b 28-Day MEK162 45mg+LEE011 250mg</title>
            <description>MEK162 45mg+LEE011 250mg</description>
          </group>
          <group group_id="O3">
            <title>Phase 1b 28-Day MEK162 30mg+LEE011 300mg</title>
            <description>MEK162 30mg+LEE011 300mg</description>
          </group>
          <group group_id="O4">
            <title>Phase 1b 28-Day MEK162 45mg+LEE011 300mg</title>
            <description>MEK162 45mg+LEE011 300mg</description>
          </group>
          <group group_id="O5">
            <title>Phase 1b 21-Day MEK162 30mg+LEE011 200mg</title>
            <description>MEK162 30mg+LEE011 200mg</description>
          </group>
          <group group_id="O6">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 200mg</title>
            <description>MEK162 45mg+LEE011 200mg</description>
          </group>
          <group group_id="O7">
            <title>Phase 1b 21-Day MEK162 30mg+LEE011 300mg</title>
            <description>MEK162 30mg+LEE011 300mg</description>
          </group>
          <group group_id="O8">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 300mg</title>
            <description>MEK162 45mg+LEE011 300mg</description>
          </group>
          <group group_id="O9">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 450mg</title>
            <description>MEK162 45mg+LEE011 450mg</description>
          </group>
          <group group_id="O10">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 600mg</title>
            <description>MEK162 45mg+LEE011 600mg</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration-time Profile (Tmax,ss) of LEE011 (Phase Ib)</title>
          <description>To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib).</description>
          <population>Analysis population consist of the pharmacokinetic analysis set (PAS), which consisted of all patients who had at least one blood sample providing evaluable PK data and received at least one dose of study drug.</population>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="2"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="5"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.25" lower_limit="0.00" upper_limit="7.5"/>
                    <measurement group_id="O2" value="5.90" lower_limit="4.00" upper_limit="7.80"/>
                    <measurement group_id="O3" value="23.93" lower_limit="23.93" upper_limit="23.93"/>
                    <measurement group_id="O4" value="2.99" lower_limit="2.00" upper_limit="4.00"/>
                    <measurement group_id="O5" value="4.00" lower_limit="1.03" upper_limit="7.87"/>
                    <measurement group_id="O6" value="1.87" lower_limit="0.50" upper_limit="4.08"/>
                    <measurement group_id="O7" value="2.03" lower_limit="1.93" upper_limit="2.12"/>
                    <measurement group_id="O8" value="4.05" lower_limit="2.08" upper_limit="6.02"/>
                    <measurement group_id="O9" value="3.92" lower_limit="2.08" upper_limit="4.13"/>
                    <measurement group_id="O10" value="1.93" lower_limit="1.02" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration-time Profile (Tmax,ss) of MEK162 (Phase Ib)</title>
        <description>To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib).</description>
        <time_frame>For the 28-day schedule the steady-state parameter time frame was Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was Cycle 1 Day 14</time_frame>
        <population>Analysis population consist of the pharmacokinetic analysis set (PAS), which consisted of all patients who had at least one blood sample providing evaluable PK data and received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1b 28-Day MEK162 45mg + LEE011 200mg</title>
            <description>MEK162 45mg + LEE011 200mg</description>
          </group>
          <group group_id="O2">
            <title>Phase 1b 28-Day MEK162 45mg+LEE011 250mg</title>
            <description>MEK162 45mg+LEE011 250mg</description>
          </group>
          <group group_id="O3">
            <title>Phase 1b 28-Day MEK162 30mg+LEE011 300mg</title>
            <description>MEK162 30mg+LEE011 300mg</description>
          </group>
          <group group_id="O4">
            <title>Phase 1b 28-Day MEK162 45mg+LEE011 300mg</title>
            <description>MEK162 45mg+LEE011 300mg</description>
          </group>
          <group group_id="O5">
            <title>Phase 1b 21-Day MEK162 30mg+LEE011 200mg</title>
            <description>MEK162 30mg+LEE011 200mg</description>
          </group>
          <group group_id="O6">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 200mg</title>
            <description>MEK162 45mg+LEE011 200mg</description>
          </group>
          <group group_id="O7">
            <title>Phase 1b 21-Day MEK162 30mg+LEE011 300mg</title>
            <description>MEK162 30mg+LEE011 300mg</description>
          </group>
          <group group_id="O8">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 300mg</title>
            <description>MEK162 45mg+LEE011 300mg</description>
          </group>
          <group group_id="O9">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 450mg</title>
            <description>MEK162 45mg+LEE011 450mg</description>
          </group>
          <group group_id="O10">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 600mg</title>
            <description>MEK162 45mg+LEE011 600mg</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration-time Profile (Tmax,ss) of MEK162 (Phase Ib)</title>
          <description>To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib).</description>
          <population>Analysis population consist of the pharmacokinetic analysis set (PAS), which consisted of all patients who had at least one blood sample providing evaluable PK data and received at least one dose of study drug.</population>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="2"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="4"/>
                <count group_id="O10" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.00" lower_limit="0.75" upper_limit="4.03"/>
                    <measurement group_id="O2" value="3.03" lower_limit="1.97" upper_limit="4.10"/>
                    <measurement group_id="O4" value="2.31" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O5" value="1.00" lower_limit="0.53" upper_limit="4.13"/>
                    <measurement group_id="O6" value="1.96" lower_limit="1.00" upper_limit="3.95"/>
                    <measurement group_id="O7" value="1.49" lower_limit="1.05" upper_limit="1.93"/>
                    <measurement group_id="O8" value="2.02" lower_limit="1.08" upper_limit="6.02"/>
                    <measurement group_id="O9" value="1.92" lower_limit="0.98" upper_limit="2.08"/>
                    <measurement group_id="O10" value="1.49" lower_limit="0.00" upper_limit="3.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration-time Profile (Accumulation Ratio, Racc_AUC) of LEE011 (Phase Ib)</title>
        <description>To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib).</description>
        <time_frame>For the 28-day schedule the steady-state parameter time frame was Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was Cycle 1 Day 14</time_frame>
        <population>Analysis population consist of the pharmacokinetic analysis set (PAS), which consisted of all patients who had at least one blood sample providing evaluable PK data and received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1b 28-Day MEK162 45mg + LEE011 200mg</title>
            <description>MEK162 45mg + LEE011 200mg</description>
          </group>
          <group group_id="O2">
            <title>Phase 1b 28-Day MEK162 45mg+LEE011 250mg</title>
            <description>MEK162 45mg+LEE011 250mg</description>
          </group>
          <group group_id="O3">
            <title>Phase 1b 28-Day MEK162 30mg+LEE011 300mg</title>
            <description>MEK162 30mg+LEE011 300mg</description>
          </group>
          <group group_id="O4">
            <title>Phase 1b 28-Day MEK162 45mg+LEE011 300mg</title>
            <description>MEK162 45mg+LEE011 300mg</description>
          </group>
          <group group_id="O5">
            <title>Phase 1b 21-Day MEK162 30mg+LEE011 200mg</title>
            <description>MEK162 30mg+LEE011 200mg</description>
          </group>
          <group group_id="O6">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 200mg</title>
            <description>MEK162 45mg+LEE011 200mg</description>
          </group>
          <group group_id="O7">
            <title>Phase 1b 21-Day MEK162 30mg+LEE011 300mg</title>
            <description>MEK162 30mg+LEE011 300mg</description>
          </group>
          <group group_id="O8">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 300mg</title>
            <description>MEK162 45mg+LEE011 300mg</description>
          </group>
          <group group_id="O9">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 450mg</title>
            <description>MEK162 45mg+LEE011 450mg</description>
          </group>
          <group group_id="O10">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 600mg</title>
            <description>MEK162 45mg+LEE011 600mg</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration-time Profile (Accumulation Ratio, Racc_AUC) of LEE011 (Phase Ib)</title>
          <description>To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib).</description>
          <population>Analysis population consist of the pharmacokinetic analysis set (PAS), which consisted of all patients who had at least one blood sample providing evaluable PK data and received at least one dose of study drug.</population>
          <units>(hr*ng/mL) / (hr*ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="2"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="5"/>
                <count group_id="O10" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.51" spread="53.9"/>
                    <measurement group_id="O2" value="2.52" spread="NA">Insufficient number of participants to calculate.</measurement>
                    <measurement group_id="O3" value="2.25" spread="NA">Insufficient number of participants to calculate.</measurement>
                    <measurement group_id="O4" value="2.29" spread="38.4"/>
                    <measurement group_id="O5" value="2.89" spread="32.8"/>
                    <measurement group_id="O6" value="2.28" spread="54.6"/>
                    <measurement group_id="O7" value="3.29" spread="165"/>
                    <measurement group_id="O8" value="3.50" spread="8.68"/>
                    <measurement group_id="O9" value="1.97" spread="45.4"/>
                    <measurement group_id="O10" value="3.95" spread="58.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration-time Profile (Accumulation Ratio, Racc_AUC) of MEK162 (Phase Ib)</title>
        <description>To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib).</description>
        <time_frame>For the 28-day schedule the steady-state parameter time frame was Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was Cycle 1 Day 14</time_frame>
        <population>Analysis population consist of the pharmacokinetic analysis set (PAS), which consisted of all patients who had at least one blood sample providing evaluable PK data and received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1b 28-Day MEK162 45mg + LEE011 200mg</title>
            <description>MEK162 45mg + LEE011 200mg</description>
          </group>
          <group group_id="O2">
            <title>Phase 1b 28-Day MEK162 45mg+LEE011 250mg</title>
            <description>MEK162 45mg+LEE011 250mg</description>
          </group>
          <group group_id="O3">
            <title>Phase 1b 28-Day MEK162 30mg+LEE011 300mg</title>
            <description>MEK162 30mg+LEE011 300mg</description>
          </group>
          <group group_id="O4">
            <title>Phase 1b 28-Day MEK162 45mg+LEE011 300mg</title>
            <description>MEK162 45mg+LEE011 300mg</description>
          </group>
          <group group_id="O5">
            <title>Phase 1b 21-Day MEK162 30mg+LEE011 200mg</title>
            <description>MEK162 30mg+LEE011 200mg</description>
          </group>
          <group group_id="O6">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 200mg</title>
            <description>MEK162 45mg+LEE011 200mg</description>
          </group>
          <group group_id="O7">
            <title>Phase 1b 21-Day MEK162 30mg+LEE011 300mg</title>
            <description>MEK162 30mg+LEE011 300mg</description>
          </group>
          <group group_id="O8">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 300mg</title>
            <description>MEK162 45mg+LEE011 300mg</description>
          </group>
          <group group_id="O9">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 450mg</title>
            <description>MEK162 45mg+LEE011 450mg</description>
          </group>
          <group group_id="O10">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 600mg</title>
            <description>MEK162 45mg+LEE011 600mg</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration-time Profile (Accumulation Ratio, Racc_AUC) of MEK162 (Phase Ib)</title>
          <description>To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib).</description>
          <population>Analysis population consist of the pharmacokinetic analysis set (PAS), which consisted of all patients who had at least one blood sample providing evaluable PK data and received at least one dose of study drug.</population>
          <units>(hr*ng/mL) / (hr*ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="2"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="5"/>
                <count group_id="O10" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.53" spread="45.8"/>
                    <measurement group_id="O2" value="7.59" spread="NA">Insufficient number of participants to calculate.</measurement>
                    <measurement group_id="O3" value="1.74" spread="NA">Insufficient number of participants to calculate.</measurement>
                    <measurement group_id="O4" value="3.39" spread="15.2"/>
                    <measurement group_id="O5" value="4.47" spread="21.5"/>
                    <measurement group_id="O6" value="2.26" spread="27.3"/>
                    <measurement group_id="O7" value="3.14" spread="161"/>
                    <measurement group_id="O8" value="3.48" spread="53.0"/>
                    <measurement group_id="O9" value="2.09" spread="53.5"/>
                    <measurement group_id="O10" value="3.06" spread="26.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration-time Profile (T1/2,ss) of LEE011 (Phase Ib)</title>
        <description>To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib).</description>
        <time_frame>For the 28-day schedule the steady-state parameter time frame was Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was Cycle 1 Day 14</time_frame>
        <population>Analysis population consist of the pharmacokinetic analysis set (PAS), which consisted of all patients who had at least one blood sample providing evaluable PK data and received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1b 28-Day MEK162 45mg + LEE011 200mg</title>
            <description>MEK162 45mg + LEE011 200mg</description>
          </group>
          <group group_id="O2">
            <title>Phase 1b 28-Day MEK162 45mg+LEE011 250mg</title>
            <description>MEK162 45mg+LEE011 250mg</description>
          </group>
          <group group_id="O3">
            <title>Phase 1b 28-Day MEK162 30mg+LEE011 300mg</title>
            <description>MEK162 30mg+LEE011 300mg</description>
          </group>
          <group group_id="O4">
            <title>Phase 1b 28-Day MEK162 45mg+LEE011 300mg</title>
            <description>MEK162 45mg+LEE011 300mg</description>
          </group>
          <group group_id="O5">
            <title>Phase 1b 21-Day MEK162 30mg+LEE011 200mg</title>
            <description>MEK162 30mg+LEE011 200mg</description>
          </group>
          <group group_id="O6">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 200mg</title>
            <description>MEK162 45mg+LEE011 200mg</description>
          </group>
          <group group_id="O7">
            <title>Phase 1b 21-Day MEK162 30mg+LEE011 300mg</title>
            <description>MEK162 30mg+LEE011 300mg</description>
          </group>
          <group group_id="O8">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 300mg</title>
            <description>MEK162 45mg+LEE011 300mg</description>
          </group>
          <group group_id="O9">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 450mg</title>
            <description>MEK162 45mg+LEE011 450mg</description>
          </group>
          <group group_id="O10">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 600mg</title>
            <description>MEK162 45mg+LEE011 600mg</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration-time Profile (T1/2,ss) of LEE011 (Phase Ib)</title>
          <description>To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib).</description>
          <population>Analysis population consist of the pharmacokinetic analysis set (PAS), which consisted of all patients who had at least one blood sample providing evaluable PK data and received at least one dose of study drug.</population>
          <units>h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="5"/>
                <count group_id="O7" value="2"/>
                <count group_id="O8" value="2"/>
                <count group_id="O9" value="4"/>
                <count group_id="O10" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.7" spread="83.6"/>
                    <measurement group_id="O2" value="32.9" spread="NA">Insufficient number of participants to calculate.</measurement>
                    <measurement group_id="O3" value="28.2" spread="NA">Insufficient number of participants to calculate.</measurement>
                    <measurement group_id="O4" value="28.0" spread="54.7"/>
                    <measurement group_id="O5" value="38.5" spread="44.4"/>
                    <measurement group_id="O6" value="26.9" spread="82.0"/>
                    <measurement group_id="O7" value="275" spread="64.5"/>
                    <measurement group_id="O8" value="49.5" spread="10.3"/>
                    <measurement group_id="O9" value="30.3" spread="17.6"/>
                    <measurement group_id="O10" value="55.3" spread="73.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration-time Profile (T1/2,ss) of MEK162 (Phase Ib)</title>
        <description>To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib).</description>
        <time_frame>For the 28-day schedule the steady-state parameter time frame was Cycle 1 Day 21, and for the 21-day schedule the steady-state parameter time frame was Cycle 1 Day 14</time_frame>
        <population>Analysis population consist of the pharmacokinetic analysis set (PAS), which consisted of all patients who had at least one blood sample providing evaluable PK data and received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1b 28-Day MEK162 45mg + LEE011 200mg</title>
            <description>MEK162 45mg + LEE011 200mg</description>
          </group>
          <group group_id="O2">
            <title>Phase 1b 28-Day MEK162 45mg+LEE011 250mg</title>
            <description>MEK162 45mg+LEE011 250mg</description>
          </group>
          <group group_id="O3">
            <title>Phase 1b 28-Day MEK162 30mg+LEE011 300mg</title>
            <description>MEK162 30mg+LEE011 300mg</description>
          </group>
          <group group_id="O4">
            <title>Phase 1b 28-Day MEK162 45mg+LEE011 300mg</title>
            <description>MEK162 45mg+LEE011 300mg</description>
          </group>
          <group group_id="O5">
            <title>Phase 1b 21-Day MEK162 30mg+LEE011 200mg</title>
            <description>MEK162 30mg+LEE011 200mg</description>
          </group>
          <group group_id="O6">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 200mg</title>
            <description>MEK162 45mg+LEE011 200mg</description>
          </group>
          <group group_id="O7">
            <title>Phase 1b 21-Day MEK162 30mg+LEE011 300mg</title>
            <description>MEK162 30mg+LEE011 300mg</description>
          </group>
          <group group_id="O8">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 300mg</title>
            <description>MEK162 45mg+LEE011 300mg</description>
          </group>
          <group group_id="O9">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 450mg</title>
            <description>MEK162 45mg+LEE011 450mg</description>
          </group>
          <group group_id="O10">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 600mg</title>
            <description>MEK162 45mg+LEE011 600mg</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration-time Profile (T1/2,ss) of MEK162 (Phase Ib)</title>
          <description>To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib).</description>
          <population>Analysis population consist of the pharmacokinetic analysis set (PAS), which consisted of all patients who had at least one blood sample providing evaluable PK data and received at least one dose of study drug.</population>
          <units>h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="11"/>
                <count group_id="O2" value="2"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="4"/>
                <count group_id="O5" value="4"/>
                <count group_id="O6" value="4"/>
                <count group_id="O7" value="2"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="4"/>
                <count group_id="O10" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.17" spread="30.6"/>
                    <measurement group_id="O2" value="7.38" spread="92.6"/>
                    <measurement group_id="O4" value="6.33" spread="81.1"/>
                    <measurement group_id="O5" value="15.0" spread="54.8"/>
                    <measurement group_id="O6" value="5.21" spread="73.2"/>
                    <measurement group_id="O7" value="15.4" spread="11.4"/>
                    <measurement group_id="O8" value="8.95" spread="23.9"/>
                    <measurement group_id="O9" value="8.73" spread="19.3"/>
                    <measurement group_id="O10" value="12.0" spread="31.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration-time Profile (CL/F) of LEE011 (Phase Ib)</title>
        <description>To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib).</description>
        <time_frame>Cycle 1 Day 1</time_frame>
        <population>Analysis population consist of the pharmacokinetic analysis set (PAS), which consisted of all patients who had at least one blood sample providing evaluable PK data and received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1b 28-Day MEK162 45mg + LEE011 200mg</title>
            <description>MEK162 45mg + LEE011 200mg</description>
          </group>
          <group group_id="O2">
            <title>Phase 1b 28-Day MEK162 45mg+LEE011 250mg</title>
            <description>MEK162 45mg+LEE011 250mg</description>
          </group>
          <group group_id="O3">
            <title>Phase 1b 28-Day MEK162 30mg+LEE011 300mg</title>
            <description>MEK162 30mg+LEE011 300mg</description>
          </group>
          <group group_id="O4">
            <title>Phase 1b 28-Day MEK162 45mg+LEE011 300mg</title>
            <description>MEK162 45mg+LEE011 300mg</description>
          </group>
          <group group_id="O5">
            <title>Phase 1b 21-Day MEK162 30mg+LEE011 200mg</title>
            <description>MEK162 30mg+LEE011 200mg</description>
          </group>
          <group group_id="O6">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 200mg</title>
            <description>MEK162 45mg+LEE011 200mg</description>
          </group>
          <group group_id="O7">
            <title>Phase 1b 21-Day MEK162 30mg+LEE011 300mg</title>
            <description>MEK162 30mg+LEE011 300mg</description>
          </group>
          <group group_id="O8">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 300mg</title>
            <description>MEK162 45mg+LEE011 300mg</description>
          </group>
          <group group_id="O9">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 450mg</title>
            <description>MEK162 45mg+LEE011 450mg</description>
          </group>
          <group group_id="O10">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 600mg</title>
            <description>MEK162 45mg+LEE011 600mg</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration-time Profile (CL/F) of LEE011 (Phase Ib)</title>
          <description>To Characterize the PK profiles of LEE011 as well as any other significant metabolites identified (Phase Ib).</description>
          <population>Analysis population consist of the pharmacokinetic analysis set (PAS), which consisted of all patients who had at least one blood sample providing evaluable PK data and received at least one dose of study drug.</population>
          <units>L/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="2"/>
                <count group_id="O4" value="5"/>
                <count group_id="O5" value="2"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="3"/>
                <count group_id="O9" value="4"/>
                <count group_id="O10" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.7" spread="75.4"/>
                    <measurement group_id="O2" value="41.2" spread="NA">Insufficient number of participants to calculate.</measurement>
                    <measurement group_id="O3" value="39.2" spread="26.7"/>
                    <measurement group_id="O4" value="67.6" spread="35.9"/>
                    <measurement group_id="O5" value="34.3" spread="81.7"/>
                    <measurement group_id="O6" value="57.2" spread="52.7"/>
                    <measurement group_id="O8" value="93.9" spread="36.1"/>
                    <measurement group_id="O9" value="78.4" spread="16.0"/>
                    <measurement group_id="O10" value="48.7" spread="68.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Plasma Concentration-time Profile (CL/F) of MEK162 (Phase Ib)</title>
        <description>To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib).</description>
        <time_frame>Cycle 1 Day 1</time_frame>
        <population>Analysis population consist of the pharmacokinetic analysis set (PAS), which consisted of all patients who had at least one blood sample providing evaluable PK data and received at least one dose of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1b 28-Day MEK162 45mg + LEE011 200mg</title>
            <description>MEK162 45mg + LEE011 200mg</description>
          </group>
          <group group_id="O2">
            <title>Phase 1b 28-Day MEK162 45mg+LEE011 250mg</title>
            <description>MEK162 45mg+LEE011 250mg</description>
          </group>
          <group group_id="O3">
            <title>Phase 1b 28-Day MEK162 30mg+LEE011 300mg</title>
            <description>MEK162 30mg+LEE011 300mg</description>
          </group>
          <group group_id="O4">
            <title>Phase 1b 28-Day MEK162 45mg+LEE011 300mg</title>
            <description>MEK162 45mg+LEE011 300mg</description>
          </group>
          <group group_id="O5">
            <title>Phase 1b 21-Day MEK162 30mg+LEE011 200mg</title>
            <description>MEK162 30mg+LEE011 200mg</description>
          </group>
          <group group_id="O6">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 200mg</title>
            <description>MEK162 45mg+LEE011 200mg</description>
          </group>
          <group group_id="O7">
            <title>Phase 1b 21-Day MEK162 30mg+LEE011 300mg</title>
            <description>MEK162 30mg+LEE011 300mg</description>
          </group>
          <group group_id="O8">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 300mg</title>
            <description>MEK162 45mg+LEE011 300mg</description>
          </group>
          <group group_id="O9">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 450mg</title>
            <description>MEK162 45mg+LEE011 450mg</description>
          </group>
          <group group_id="O10">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 600mg</title>
            <description>MEK162 45mg+LEE011 600mg</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration-time Profile (CL/F) of MEK162 (Phase Ib)</title>
          <description>To Characterize the PK profiles of MEK162 as well as any other significant metabolites identified (Phase Ib).</description>
          <population>Analysis population consist of the pharmacokinetic analysis set (PAS), which consisted of all patients who had at least one blood sample providing evaluable PK data and received at least one dose of study drug.</population>
          <units>L/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="1"/>
                <count group_id="O3" value="1"/>
                <count group_id="O4" value="1"/>
                <count group_id="O5" value="2"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="2"/>
                <count group_id="O8" value="1"/>
                <count group_id="O9" value="2"/>
                <count group_id="O10" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.5" spread="36.3"/>
                    <measurement group_id="O2" value="35.9" spread="NA">Insufficient number of participants to calculate.</measurement>
                    <measurement group_id="O3" value="17.8" spread="NA">Insufficient number of participants to calculate.</measurement>
                    <measurement group_id="O4" value="35.5" spread="NA">Insufficient number of participants to calculate.</measurement>
                    <measurement group_id="O5" value="17.9" spread="80.7"/>
                    <measurement group_id="O6" value="23.9" spread="83.6"/>
                    <measurement group_id="O7" value="37.2" spread="23.0"/>
                    <measurement group_id="O8" value="15.9" spread="NA">Insufficient number of participants to calculate.</measurement>
                    <measurement group_id="O9" value="20.8" spread="45.8"/>
                    <measurement group_id="O10" value="10.2" spread="NA">Insufficient number of participants to calculate.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Drug Reactions</title>
        <description>Safety and tolerability will be characterized through the incidence and severity of adverse drug reactions, serious adverse drug reactions, changes in hematology and chemistry values, vital signs, electrocardiograms (ECGs), dose interruptions, dose reduction and dose intensity.</description>
        <time_frame>Approximately 12 months after FPFV</time_frame>
        <population>Analysis group consists of the safety set, which included all patients who received at least 1 dose of ribociclib or binimetinib and had at least 1 postbaseline safety assessment.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1b 28-Day MEK162 45mg + LEE011 200mg</title>
            <description>MEK162 45mg + LEE011 200mg</description>
          </group>
          <group group_id="O2">
            <title>Phase 1b 28-Day MEK162 45mg+LEE011 250mg</title>
            <description>MEK162 45mg+LEE011 250mg</description>
          </group>
          <group group_id="O3">
            <title>Phase 1b 28-Day MEK162 30mg+LEE011 300mg</title>
            <description>MEK162 30mg+LEE011 300mg</description>
          </group>
          <group group_id="O4">
            <title>Phase 1b 28-Day MEK162 45mg+LEE011 300mg</title>
            <description>MEK162 45mg+LEE011 300mg</description>
          </group>
          <group group_id="O5">
            <title>Phase 1b 21-Day MEK162 30mg+LEE011 200mg</title>
            <description>MEK162 30mg+LEE011 200mg</description>
          </group>
          <group group_id="O6">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 200mg</title>
            <description>MEK162 45mg+LEE011 200mg</description>
          </group>
          <group group_id="O7">
            <title>Phase 1b 21-Day MEK162 30mg+LEE011 300mg</title>
            <description>MEK162 30mg+LEE011 300mg</description>
          </group>
          <group group_id="O8">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 300mg</title>
            <description>MEK162 45mg+LEE011 300mg</description>
          </group>
          <group group_id="O9">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 450mg</title>
            <description>MEK162 45mg+LEE011 450mg</description>
          </group>
          <group group_id="O10">
            <title>Phase 1b 21-Day MEK162 45mg+LEE011 600mg</title>
            <description>MEK162 45mg+LEE011 600mg</description>
          </group>
          <group group_id="O11">
            <title>Phase 2: MEK162 45mg+LEE011 200mg</title>
            <description>MEK162 45mg+LEE011 200mg</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Drug Reactions</title>
          <description>Safety and tolerability will be characterized through the incidence and severity of adverse drug reactions, serious adverse drug reactions, changes in hematology and chemistry values, vital signs, electrocardiograms (ECGs), dose interruptions, dose reduction and dose intensity.</description>
          <population>Analysis group consists of the safety set, which included all patients who received at least 1 dose of ribociclib or binimetinib and had at least 1 postbaseline safety assessment.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="4"/>
                <count group_id="O4" value="6"/>
                <count group_id="O5" value="5"/>
                <count group_id="O6" value="6"/>
                <count group_id="O7" value="2"/>
                <count group_id="O8" value="4"/>
                <count group_id="O9" value="9"/>
                <count group_id="O10" value="6"/>
                <count group_id="O11" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="6"/>
                    <measurement group_id="O5" value="5"/>
                    <measurement group_id="O6" value="6"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="4"/>
                    <measurement group_id="O9" value="9"/>
                    <measurement group_id="O10" value="6"/>
                    <measurement group_id="O11" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DoR) - Phase 2</title>
        <description>To assess clinical safety as per RECIST 1.1. Evaluation will occur continuously throughout the trial until progression, or death due to underlying cancer.&#xD;
Please note: As clinicaltrials.gov only allows numerical data entry, the value of 999 indicates &quot;not estimable&quot; for confidence interval.</description>
        <time_frame>Approximately 12 months after the FPFV</time_frame>
        <population>Analysis population consist of the Full Analysis Set, which included all patients who received at least one dose of binimetinib or ribociclib and was used for the analysis of all endpoints unless noted otherwise.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Dose Expansion</title>
            <description>The dose-expansion phase was initiated with a newly recruited group of patients.&#xD;
Binimetinib 45 mg BID + ribociclib 200 mg QD on 28-day schedule</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (DoR) - Phase 2</title>
          <description>To assess clinical safety as per RECIST 1.1. Evaluation will occur continuously throughout the trial until progression, or death due to underlying cancer.&#xD;
Please note: As clinicaltrials.gov only allows numerical data entry, the value of 999 indicates &quot;not estimable&quot; for confidence interval.</description>
          <population>Analysis population consist of the Full Analysis Set, which included all patients who received at least one dose of binimetinib or ribociclib and was used for the analysis of all endpoints unless noted otherwise.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.3" lower_limit="4.1" upper_limit="999"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progression (TTP) - Phase 2</title>
        <description>To assess clinical safety as per RECIST 1.1. Evaluation will occur continuously throughout the trial until progression, or death due to underlying cancer.</description>
        <time_frame>Approximately 12 months after the FPFV</time_frame>
        <population>Analysis population consist of the Full Analysis Set, which included all patients who received at least one dose of binimetinib or ribociclib and was used for the analysis of all endpoints unless noted otherwise.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Dose Expansion</title>
            <description>The dose-expansion phase was initiated with a newly recruited group of patients.&#xD;
Binimetinib 45 mg BID + ribociclib 200 mg QD on 28-day schedule</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progression (TTP) - Phase 2</title>
          <description>To assess clinical safety as per RECIST 1.1. Evaluation will occur continuously throughout the trial until progression, or death due to underlying cancer.</description>
          <population>Analysis population consist of the Full Analysis Set, which included all patients who received at least one dose of binimetinib or ribociclib and was used for the analysis of all endpoints unless noted otherwise.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" lower_limit="3.5" upper_limit="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression Free Survival (PFS) - Phase 1b and Phase 2</title>
        <description>To assess clinical safety as per RECIST 1.1. Evaluation will occur continuously throughout the trial until progression, or death due to underlying cancer.&#xD;
In the Phase 1b part, patients were combined for purposes of PFS analyses based on schedule received, since too few patients received any individual dose level to allow for valid PFS estimates within the respective dose levels. This is how the data were analyses and presented for the clinical study report.</description>
        <time_frame>Approximately 12 months after the FPFV</time_frame>
        <population>Analysis population consist of the Full Analysis Set, which included all patients who received at least one dose of binimetinib or ribociclib and was used for the analysis of all endpoints unless noted otherwise.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 1b 28-Day Schedule</title>
            <description>A combined total of 61 patients were treated in the 28-day (n=29) and 21-day (n=32) treatment cycles, and all patients discontinued treatment. The starting dose in the 28-day schedule was binimetinib 45 mg BID + ribociclib 200 mg QD.&#xD;
28-Day Schedule: ribociclib was taken QD for 21 consecutive days followed by a 7-day planned break.&#xD;
Binimetinib was taken BID on a continuous dosing schedule.</description>
          </group>
          <group group_id="O2">
            <title>Phase 1b 21-Day Schedule</title>
            <description>A combined total of 61 patients were treated in the 28-day (n=29) and 21-day (n=32) treatment cycles, and all patients discontinued treatment. The starting dose in the 21-day schedule was binimetinib 30 mg BID + ribociclib 200 mg QD.&#xD;
21-Day Schedule: ribociclib QD and binimetinib BID were taken QD for 14 consecutive days followed by a 7-day planned break.</description>
          </group>
          <group group_id="O3">
            <title>Phase 2 (Dose-expansion Phase)</title>
            <description>The dose-expansion phase was initiated with a newly recruited group of patients.&#xD;
A total of 41 patients were treated, and all patients (100%) discontinued treatment. Based on the recommendations of the dose-escalation meetings between the Sponsor and the Investigators, the RP2D and schedule for the combination of binimetinib and ribociclib to be used for the dose-expansion phase of the study was binimetinib 45 mg BID + ribociclib 200 mg QD on the 28-day schedule.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival (PFS) - Phase 1b and Phase 2</title>
          <description>To assess clinical safety as per RECIST 1.1. Evaluation will occur continuously throughout the trial until progression, or death due to underlying cancer.&#xD;
In the Phase 1b part, patients were combined for purposes of PFS analyses based on schedule received, since too few patients received any individual dose level to allow for valid PFS estimates within the respective dose levels. This is how the data were analyses and presented for the clinical study report.</description>
          <population>Analysis population consist of the Full Analysis Set, which included all patients who received at least one dose of binimetinib or ribociclib and was used for the analysis of all endpoints unless noted otherwise.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
                <count group_id="O2" value="32"/>
                <count group_id="O3" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" lower_limit="3.5" upper_limit="9.2"/>
                    <measurement group_id="O2" value="4.1" lower_limit="2.8" upper_limit="6.1"/>
                    <measurement group_id="O3" value="3.7" lower_limit="3.5" upper_limit="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival (OS) - Phase ll</title>
        <description>To assess clinical safety as per RECIST 1.1. Evaluation will occur continuously throughout the trial until progression, or death due to underlying cancer.</description>
        <time_frame>Approximately 12 months after the FPFV</time_frame>
        <population>Analysis population consist of the Full Analysis Set, which included all patients who received at least one dose of binimetinib or ribociclib and was used for the analysis of all endpoints unless noted otherwise.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Dose Expansion</title>
            <description>The dose-expansion phase was initiated with a newly recruited group of patients.&#xD;
Binimetinib 45 mg BID + ribociclib 200 mg QD on 28-day schedule</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS) - Phase ll</title>
          <description>To assess clinical safety as per RECIST 1.1. Evaluation will occur continuously throughout the trial until progression, or death due to underlying cancer.</description>
          <population>Analysis population consist of the Full Analysis Set, which included all patients who received at least one dose of binimetinib or ribociclib and was used for the analysis of all endpoints unless noted otherwise.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.3" lower_limit="9.3" upper_limit="14.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Best Overall Response (BOR) - Phase II</title>
        <description>To assess clinical safety according to RECIST 1.1. Evaluation will occur continuously throughout the trial until progression, or death due to underlying cancer.</description>
        <time_frame>Approximately 12 months after the FPFV</time_frame>
        <population>Analysis population consist of the Full Analysis Set, which included all patients who received at least one dose of binimetinib or ribociclib and was used for the analysis of all endpoints unless noted otherwise.</population>
        <group_list>
          <group group_id="O1">
            <title>Phase 2: Dose Expansion</title>
            <description>The dose-expansion phase was initiated with a newly recruited group of patients.&#xD;
Binimetinib 45 mg BID + ribociclib 200 mg QD on 28-day schedule</description>
          </group>
        </group_list>
        <measure>
          <title>Best Overall Response (BOR) - Phase II</title>
          <description>To assess clinical safety according to RECIST 1.1. Evaluation will occur continuously throughout the trial until progression, or death due to underlying cancer.</description>
          <population>Analysis population consist of the Full Analysis Set, which included all patients who received at least one dose of binimetinib or ribociclib and was used for the analysis of all endpoints unless noted otherwise.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Complete Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Stable Disease</title>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progressive Disease</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Non-CR/Non-PD</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events (AE) were collected during the study, which began in June 2013 and concluded February 2018. After signing of the informed consent until 30 days after study treatment discontinuation.</time_frame>
      <desc>An AE is defined as the appearance of (or worsening of any pre-existing) undesirable sign(s), symptom(s), or medical condition(s) that occur after patient's signed informed consent has been obtained.</desc>
      <group_list>
        <group group_id="E1">
          <title>Phase 1b - 28 Day MEK162 45mg+LEE011 200mg</title>
          <description>MEK162 45mg BID+LEE011 200mg QD</description>
        </group>
        <group group_id="E2">
          <title>Phase 1b - 28 Day MEK162 45mg+LEE011 250mg</title>
          <description>MEK162 45mg BID+LEE011 250mg QD</description>
        </group>
        <group group_id="E3">
          <title>Phase 1b - 28 Day MEK162 30mg+LEE011 300mg</title>
          <description>MEK162 30mg BID+LEE011 300mg QD</description>
        </group>
        <group group_id="E4">
          <title>Phase 1b - 28 Day MEK162 45mg+LEE011 300mg</title>
          <description>MEK162 45mg BID+LEE011 300mg QD</description>
        </group>
        <group group_id="E5">
          <title>Phase 1b - 21 Day MEK162 30mg+LEE011 200mg</title>
          <description>MEK162 30mg BID+LEE011 200mg QD</description>
        </group>
        <group group_id="E6">
          <title>Phase 1b - 21 Day MEK162 45mg+LEE011 200mg</title>
          <description>MEK162 45mg BID+LEE011 200mg QD</description>
        </group>
        <group group_id="E7">
          <title>Phase 1b - 21 Day MEK162 30mg+LEE011 300mg</title>
          <description>MEK162 30mg BID+LEE011 300mg QD</description>
        </group>
        <group group_id="E8">
          <title>Phase 1b - 21 Day MEK162 45mg+LEE011 300mg</title>
          <description>MEK162 45mg BID+LEE011 300mg QD</description>
        </group>
        <group group_id="E9">
          <title>Phase 1b - 21 Day MEK162 45mg+LEE011 450mg</title>
          <description>MEK162 45mg BID+LEE011 450mg QD</description>
        </group>
        <group group_id="E10">
          <title>Phase 1b - 21 Day MEK162 45mg+LEE011 600mg</title>
          <description>MEK162 45mg BID+LEE011 600mg QD</description>
        </group>
        <group group_id="E11">
          <title>Phase 2 - Dose Expansion Phase</title>
          <description>The dose-expansion phase was initiated with a newly recruited group of patients.&#xD;
Binimetinib 45 mg BID + ribociclib 200 mg QD on 28-day schedule</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA Version 19.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="23" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="22" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Small intestinal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Rectal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Intestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Staphylococcal bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Neutrophil</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypervolaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tumour haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Intracranial tumour haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Slow speech</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Hemiplegia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Micturition frequency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Obstructive airways</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA Version 19.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="41" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Aeaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="10" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Granulocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Cardio-respiratiory arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Chorioretinopathy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="6" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Macular oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Subretinal fluid</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Detachment of retinal pigment epithelium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Chorioretinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Periorbital oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Retinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="22" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="21" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="14" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="8" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Gingival pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Glossodynia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="18" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="15" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="11" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="6" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Astenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="2"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of the sponsor's agreements with its investigators may vary. However, the sponsor does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of pooled data (i.e., data from all sites) in the clinical trials.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Pfizer</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

